Fig. 2: Mouse immunogenicity.
From: BNT162b vaccines protect rhesus macaques from SARS-CoV-2
We injected BALB/c mice (n = 8) intramuscularly with a single dose of one of the BNT162b vaccine candidates or a buffer control. Geometric means of each group ± 95% confidence interval are shown. Day-28 P values compared to control (multiple comparison of mixed-effect analysis using Dunnett’s multiple comparisons test) for the single time points and groups are provided in a, b. a, Levels of RBD-specific IgG in sera of mice immunized using 5 μg of BNT162b1 or BNT162b2, determined by enzyme-linked immunosorbent assay (ELISA). For day-0 values, a prescreening of randomly selected mice was performed (n = 4). Extended Data Figure 3a, b shows IgG levels with lower BNT162b doses and sera testing for detection of S1. b, Pseudovirus-based VSV-SARS-CoV-2 50% neutralization titres (pVNT50) in sera of mice immunized using BNT162b1 (left) or BNT162b2 (right). Extended Data Figure 3g–i provides the number of infected cells per well with serum samples drawn 28 d after injection and titre correlation to a SARS-CoV-2 virus neutralization assay. For cellular response analysis in c, d, splenocytes of BALB/c mice (n = 8, unless stated otherwise) injected intramuscularly with BNT162b1 (green) or BNT162b2 (pink) were restimulated ex vivo with full-length S peptide mix or cell culture medium. Symbols represent individual mice. Heights of bars indicate the mean. P values compare immunized groups with the control (parametric, two-tailed paired t-test). c, IFNγ ELISpot of splenocytes 12 d after injection with 5 μg of one of the BNT162b vaccines. d, Cytokine production by splenocytes 28 d after injection with 0.2 μg BNT162b1 or 1 μg BNT162b2, determined by bead-based multiplex analysis (BNT162b2: n = 7 for IL-4, IL-5 and IL-13, one outlier removed by the ROUT method (Q = 1%) for the S peptide stimulated samples).
